Pure Global

VISITECT CD4 - India CDSCO Medical Device Registration

VISITECT CD4 is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2018/000005_ec00bb92ff0d4245dc343c83537bc3f8_e1ea23b093607e2b6d5169348883c762. This device is marketed under the brand name Pathozyme® Ovarian Cancer Antigen Ag 125 ELISA. The license holder is Omega DX (Asia) Private Limited, and it is classified as Device Class Class C. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class C
VISITECT CD4
UID: IMP/IVD/2018/000005_ec00bb92ff0d4245dc343c83537bc3f8_e1ea23b093607e2b6d5169348883c762

Brand Name

Pathozyme® Ovarian Cancer Antigen Ag 125 ELISA

Device Class

Class C

Approving Authority

CDSCO

Product Information

The VISTECT CD4 Rapid Test is a semi-quantitative assay for the estimation of CD4 protein on the surface of CD4+ T cells in human whole bood to indicate whether the level is above or below 350 cells/uL within pre-diagnosed HIV patients

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing